| Literature DB >> 9760161 |
M Jensen1, U Winkler, O Manzke, V Diehl, A Engert.
Abstract
In this report we present a patient with B-cell chronic lymphocytic leukemia who developed an acute tumor lysis syndrome after administration of the human anti-CD20 antibody IDEC-C2B8 (RITUXIMAB) in standard dose of 375 mg/m2. IDEC-C2B8 has been demonstrated to have only mild and tolerable side effects in patients with follicular lymphoma. In these trials patients with lymphocytosis >5000/microl were excluded. Physicians must be aware of this hitherto unreported phenomenon in patients with high CD20-positive blood counts.Entities:
Mesh：
Substances：
Year: 1998 PMID： 9760161 DOI： 10.1007/s002770050419
Source DB: PubMed Journal: Ann Hematol ISSN： 0939-5555 Impact factor: 3.673